PTO/SB/08a (08-03)

Approved for use through 07/31/2008. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449A/PTO Application Number 10/705,262 INFORMATION DISCLOSURE November 12, 2003 Filing Date STATEMENT BY APPLICANT WARRINGTON et al. First Named Inventor **Group Art Unit** (use as many sheets as necessary) **Examiner Name** Sheet of 2 **Attorney Docket Number WARRINGTON=1** 

			U.S. PA	TENT DOCUMENTS	
F	011-	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or	Pages, Columns, Lines, Where
Examiner nitials*	Cite No.1	Number-Kind Code <sup>2 (d known)</sup>	MIMI-UU-TTTT	Applicant of Cited Document	Relevant Passages or Relevant Figures Appear
<b>Y</b> Z	AA	US-5,773,423	05-30-1998	Jacobson et al.	
		US-			
		US-	-		
		US-			_
		US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Foreign Patent Number Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>3</sup> (if known)	Publication Date MM-DD-YYYY	Name of Paterilee of Applicant	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	τ°
						_
		·		-		
Examin				Date		

Signature

Considered

<sup>\*</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \*Applicant's unique citation designation number (optional). \*See Kind Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. \*Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). \*For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \*S Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. \*Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE are required to respond to a collection of information unless it contains a valid OMB control number.

Under the Paperwork Reduction

Complete if Known Substitute for form 1449A/PTC **Application Number** 10/705,262 **INFORMATION DISCLOSURE** Filing Date November 12, 2003 STATEMENT BY APPLICANT WARRINGTON et al. First Named Inventor **Group Art Unit** (use as many sheets as necessary) **Examiner Name** WARRINGTON=1 Sheet of 2 **Attorney Docket Number** 

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Examiner Cite magazine, jo		Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, agazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published		
R	AB BAR-YEHUDA et al., "Agonists To The A3 Adenosine Receptor Induce G-CSF Production Via NF-kB Activation A New Class Of Myeloprotective Agents", Experimental Hematology 30: (2002), 1390-1398			
į	AC	BAR-YEHUDA et al., "Resistance of Muscle to Tumor Metastases: A Role for A3 Adenosine Receptor Agonists", Neoplasia (2001), Vol. 3, No. 2, 125-131.		
	AD	FISHMAN et al., "Adenosine Acts As An Inhibitor Of Lymphoma Cell Growth: A Major Role For The A3 Adenosine Receptor", European Journal Of Cancer, 36: (2000), 1452-1458.		
1/	AE	FISHMAN et al., "Adenosine Acts As A Chemoprotective Agent By Stimulating G-CSF Production: A Role For A1 and A3 Adenosine Receptors", Journal Of Cellular Physiology, 183: (2000), 393-398.		
PL	AF	FISHMAN et al., "Targeting The A3 Adenosine Receptor For Cancer Therapy: Inhibition Of Prostate Carcinoma Cell Growth By A3AR Agonist", Anticancer Research, 23: (2003) 2077-2083.		

Examiner Signature	Matrick Lenie	Date Considered	5-15-06

<sup>\*</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.